Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys.

Byrnes-Blake KA, Pederson S, Klucher KM, Anderson-Haley M, Miller DM, Lopez-Talavera JC, Freeman JA.

J Interferon Cytokine Res. 2012 May;32(5):198-206. doi: 10.1089/jir.2011.0075. Epub 2012 Jan 26.

PMID:
22280056
2.

IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease.

Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, Klucher KM, Doyle SE, Neurath MF, Finotto S, Andreakos E.

EMBO Mol Med. 2011 Jun;3(6):348-61. doi: 10.1002/emmm.201100142. Epub 2011 May 3.

3.

Interferon lambda as a potential new therapeutic for hepatitis C.

Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE.

Ann N Y Acad Sci. 2009 Dec;1182:80-7. doi: 10.1111/j.1749-6632.2009.05241.x.

PMID:
20074277
4.

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes.

Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM.

Hepatology. 2006 Oct;44(4):896-906.

PMID:
17006906
5.

Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells.

Osterlund P, Veckman V, Sirén J, Klucher KM, Hiscott J, Matikainen S, Julkunen I.

J Virol. 2005 Aug;79(15):9608-17.

6.

IL-28, IL-29 and their class II cytokine receptor IL-28R.

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM.

Nat Immunol. 2003 Jan;4(1):63-8. Epub 2002 Dec 2.

PMID:
12469119
7.

Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.

Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ.

Oncogene. 2001 May 10;20(21):2636-46.

8.

The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.

Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM, Griffin JD.

Blood. 1999 Dec 15;94(12):4233-46.

PMID:
10590068
9.

Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.

Klucher KM, Lopez DV, Daley GQ.

Blood. 1998 May 15;91(10):3927-34.

PMID:
9573031
10.

A novel method to isolate cells with conditional gene expression using fluorescence activated cell sorting.

Klucher KM, Gerlach MJ, Daley GQ.

Nucleic Acids Res. 1997 Dec 1;25(23):4858-60.

12.

A gene encoding a host-specific elicitor protein of Phytophthora parasitica.

Kamoun S, Klucher KM, Coffey MD, Tyler BM.

Mol Plant Microbe Interact. 1993 Sep-Oct;6(5):573-81.

PMID:
8274771
13.
16.

Human cytomegalovirus early gene expression.

Spector DH, Klucher KM, Rabert DK, Wright DA.

Curr Top Microbiol Immunol. 1990;154:21-45. Review. No abstract available.

PMID:
2161321
17.
18.

Tannin-protein interactions.

Hagerman AE, Klucher KM.

Prog Clin Biol Res. 1986;213:67-76. Review. No abstract available.

PMID:
3520596

Supplemental Content

Loading ...
Support Center